TScan Therapeutics, Inc. (NASDAQ:TCRX – Free Report) – Analysts at HC Wainwright boosted their Q3 2024 earnings estimates for TScan Therapeutics in a report issued on Tuesday, August 13th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.31) per share for the quarter, up from their prior forecast of ($0.36). HC Wainwright has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.25) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q4 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.24) EPS, FY2025 earnings at ($1.31) EPS, FY2026 earnings at ($1.20) EPS, FY2027 earnings at ($0.76) EPS and FY2028 earnings at ($0.20) EPS.
TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. The firm had revenue of $0.54 million for the quarter, compared to the consensus estimate of $1.55 million. TScan Therapeutics had a negative return on equity of 61.13% and a negative net margin of 653.50%.
Get Our Latest Analysis on TCRX
TScan Therapeutics Stock Down 0.9 %
TCRX stock opened at $5.74 on Thursday. The company has a market cap of $303.43 million, a price-to-earnings ratio of -4.48 and a beta of 0.83. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.23 and a current ratio of 5.23. The business’s 50-day moving average is $6.70 and its two-hundred day moving average is $7.15. TScan Therapeutics has a fifty-two week low of $1.97 and a fifty-two week high of $9.69.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP purchased a new position in TScan Therapeutics during the second quarter valued at approximately $70,000. The Manufacturers Life Insurance Company bought a new stake in shares of TScan Therapeutics during the 2nd quarter valued at $90,000. Pale Fire Capital SE lifted its stake in shares of TScan Therapeutics by 30.2% during the 4th quarter. Pale Fire Capital SE now owns 21,573 shares of the company’s stock valued at $126,000 after buying an additional 4,998 shares in the last quarter. Cornercap Investment Counsel Inc. bought a new position in TScan Therapeutics in the 2nd quarter worth $134,000. Finally, Cannon Global Investment Management LLC purchased a new stake in TScan Therapeutics in the 1st quarter worth $139,000. 82.83% of the stock is currently owned by institutional investors.
About TScan Therapeutics
TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.
See Also
- Five stocks we like better than TScan Therapeutics
- What is Short Interest? How to Use It
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- Where Do I Find 52-Week Highs and Lows?
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- Consumer Staples Stocks, Explained
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.